1-{[5-(2-Oxohexahydro-1H-Thieno[3,4-D]Imidazol-4-Yl)Pentanoyl]Oxy}Pyrrolidine-2,5-Dione

What Determines Conjugation Stoichiometry Variance Across Immunodiagnostic Antibody Batches in Full-Scale CLIA Kit Manufacturing?

The predominant industrial deployment of 1-{[5-(2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoyl]oxy}pyrrolidine-2,5-dione resides in the production of biotinylated detector antibodies integrated into chemiluminescence immunoassay (CLIA) kits functioning on fully automated random-access analyzers such as the Roche cobas e801 or Abbott Alinity i series. In this context, batch-to-batch consistency in biotin incorporation levels is the central release criterion, as drift exceeding ±0.8 biotin moieties per IgG molecule shifts the signal-to-noise ratio beyond the validated acceptance window defined in the analytical target profile. Compliance is structured around ISO 13485:2016 Clause 7.3.3 (Design and Development Inputs) and IVDR (EU) 2017/746 Annex I General Safety and Performance Requirements, with ancillary adherence to USP <1043> for ancillary materials used in biologic manufacture. The recommended addition ratio is empirically established at a molar input of 20:1 (biotin NHS ester:monoclonal IgG) using a protein concentration of 4–8 mg/mL in 0.1 M sodium bicarbonate buffer at pH 8.3. The activated ester is dissolved in anhydrous DMSO at 10 mg/mL and introduced via a syringe pump at a controlled flow rate of 0.5 mL/min into a jacketed glass reactor maintained at 25 °C ± 0.5 °C under low-shear overhead stirring at 80 rpm. Reaction time is capped at 30 min to minimize alkaline denaturation of the Fc region. Downstream purification employs a two-step ÄKTA pure 150 system: initial desalting and buffer exchange into 20 mM sodium phosphate, 150 mM NaCl, pH 7.2 using a HiPrep 26/10 Desalting column, followed by aggregate removal through a Superdex 200 Increase 10/300 GL column with a flow rate of 0.75 mL/min. The pooled monomeric fraction is concentrated by tangential flow filtration on a Pellicon 3 Cassette with a 30 kDa Ultracel membrane to a target protein concentration of 2.0 mg/mL. Formulation for lyophilization includes 1% (w/v) trehalose dihydrate, 0.01% polysorbate 20, and the biotinylated antibody is dispensed into 2R type I borosilicate glass vials at a fill volume of 0.5 mL. Lyophilization is performed on a SP Scientific LyoStar 3 unit with shelf temperature ramping from −45 °C to +30 °C over 48 h, maintaining chamber pressure at 60 mTorr. The terminal finished product is a lyophilized biotinylated mouse anti-human TSH detector antibody used as a reconstitutable component in third-generation TSH CLIA kits, specified to deliver a biotin-to-protein molar ratio between 3.0 and 4.5 as quantified by the HABA-avidin assay.

For high-throughput clinical analyzers requiring stable biotin-streptavidin bridging in sandwich immunoassays where the detection antibody must retain no more than 20% loss in dissociation constant (Kd) post-conjugation, the lysine-directed acylation is carried out with an intentional under-stoichiometric ratio relative to the total solvent-accessible primary amines. Process controls document that a molar input ratio of 12:1 applied to a rabbit polyclonal anti-procalcitonin IgG fraction yields 2.4–2.8 biotins per antibody, preserving analyte-binding by minimizing epitope masking at the hypervariable loops. The reaction is terminated by addition of Tris-HCl pH 7.5 to a final concentration of 50 mM, scavenging residual NHS ester. A subsequent dialysis against 10 L of 10 mM PBS using a 20 kDa molecular weight cut-off cellulose ester membrane in a GMP cleanroom (ISO 14644-1 Class 7) completes the removal of N-hydroxysuccinimide by-product, which if retained at levels exceeding 2 ppm depresses conjugate stability during accelerated storage at 37 °C. The final solution is sterile-filtered through a 0.22 µm PVDF membrane and transferred as a regulated starting material into a filling line for liquid-stable ready-to-use immunoassay reagent bottles conforming to ICH Q1A(R2) stability testing requirements. The finished product in this configuration remains active for 24 months at 2–8 °C with less than 5% antigen-binding capacity loss.

Oligonucleotide 5′-Biotinylation via NHS Ester Chemistry — C18 RP-HPLC Purification Parameters and Lot Release for IVD Probe Use

Nucleic acid detection workflows in lateral flow assays and bead-based Luminex xMAP technology require 5′-biotinylated oligonucleotide probes where the biotin-avidin interaction captures amplicons onto test line or microsphere surfaces. Manufacturing of these probes at the 100 µmol scale under ISO 13485:2016 quality management systems and ISO 18385:2016 (minimizing risk of human DNA contamination in forensic PCR reagents) employs a 5′-aminohexyl modified oligonucleotide prepared by standard phosphoramidite synthesis. The NHS ester is reacted in 0.1 M sodium borate buffer, pH 8.5, with the amino-modified oligonucleotide at a molar ratio of 10:1 (biotin-NHS:oligonucleotide) for 2 h at 37 °C in a light-protected vial. Following reaction, the crude mixture is desalted on a Sephadex G-25 PD-10 column to remove unreacted small molecules before loading onto a preparative reversed-phase HPLC column (Waters XBridge BEH C18, 10 × 150 mm, 5 µm particle size). A gradient of 5–25% acetonitrile in 0.1 M triethylammonium acetate, pH 7.0, over 40 min at a flow rate of 3.0 mL/min resolves the biotinylated product from the non-biotinylated parent oligonucleotide, with the product eluting approximately 2–3 min later due to increased hydrophobicity. Fraction pooling criteria are set to a purity threshold of ≥96% as determined by analytical HPLC with UV detection at 260 nm. Pooled fractions are dried under vacuum in a Genevac HT-4X evaporator, resuspended in nuclease-free water, and quantified by UV spectrophotometry using the calculated extinction coefficient. The terminal finished product is a lyophilized or liquid oligonucleotide probe (e.g., a 35-mer biotinylated capture probe specific for Salmonella invA gene) supplied in vials at 100 µM concentration, intended for incorporation into PCR-ELISA detection kits regulated under 21 CFR 866.3160. Functional lot release testing includes hybridization efficiency with a complementary biotin-free detector probe and subsequent capture onto streptavidin-coated 96-well plates to confirm signal linearity across the range of 10³–10⁶ target copies.

Production-scale conjugation of calf intestinal alkaline phosphatase with the NHS ester for employment in signal amplification modules of enzyme-linked immunosorbent assays introduces a strict solvent restraint: the enzyme must be exposed to no more than 2% (v/v) DMSO throughout the coupling step to prevent irreversible loss of tertiary structure. The reaction is therefore executed by adding the biotin-NHS ester stock at 1 mg/mL in dimethylformamide dropwise to the enzyme solution at 2.5 mg/mL in triethanolamine-buffered saline, pH 8.0, containing 5 mM MgCl₂ and 0.1 mM ZnCl₂ as cofactor stabilizers, reaching a final molar ratio of 4:1. The mixture is incubated for 1 h at 22 °C protected from light, after which excess reagent is quenched by glycine at 100 mM. The biotinylated alkaline phosphatase is purified by size-exclusion chromatography on a HiLoad 16/600 Superdex 200 pg column equilibrated with 50 mM Tris-HCl, 150 mM NaCl, 0.1 mM MgCl₂, pH 7.6. Collected fractions are concentrated and aliquoted into single-use working volumes, then mixed with a cryoprotectant matrix of 2% (w/v) mannitol and 1% (w/v) BSA prior to lyophilization. Finished lyophilized biotinylated alkaline phosphatase polymer is a critical raw material for the Saureus β-lactamase immunoassay platform relying on streptavidin-biotin signal amplification, where it is reconstituted with p-nitroaniline phosphate substrate buffer. Because any residual aggregated enzyme increases non-specific signal above 0.15 absorbance units, a parallel aggregate assay by dynamic light scattering using a Malvern Zetasizer Nano ZS is mandatory on each batch, with a polydispersity index release criterion of <0.2.

Biotinylated Carrier Protein Intermediates for Conjugate Vaccine Workflows — CRM197 and Tetanus Toxoid Modification

In glycoconjugate vaccine manufacturing, biotin is selectively anchored onto carrier proteins such as CRM197 cross-reactive material or tetanus toxoid through NHS ester chemistry as part of a modular construct for pre-targeting strategies or as an intermediate for site-specific polysaccharide conjugation. The chemical step must operate under conditions that do not pre-activate the carrier’s ε-amino groups beyond the degree required for subsequent polysaccharide coupling, typically limiting biotin occupancy to fewer than 1.5 biotins per carrier. The addition ratio is rigorously controlled at a molar input of 1.2:1 (biotin NHS ester:CRM197 monomer) in 0.1 M HEPES, pH 7.8, with the reaction proceeding at 4 °C for 90 min to decelerate acylation kinetics and avoid a heterogenous population. After quenching with 10 mM ethanolamine, the mixture is subjected to anion-exchange chromatography on a Q Sepharose Fast Flow column in a linear NaCl gradient from 0–500 mM at pH 8.0, which separates mono-biotinylated CRM197 from multi-biotinylated and unreacted protein species. The product peak is desalted and buffer exchanged into 10 mM phosphate buffer, pH 7.0, by tangential flow filtration using a 30 kDa PES cassette. Compliance for this intermediate destined for a Phase II clinical trial is structured around 21 CFR 211 (cGMP for finished pharmaceuticals) and ICH Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, given its status as a critical raw material for the subsequent reductive amination conjugation to a meningococcal serogroup C oligosaccharide. The finished product is a sterile-filtered (0.22 µm), mono-biotinylated CRM197 solution at 5.0 mg/mL dispensed into 10 mL single-use bags and stored at −70 °C, with potency verified by polysaccharide conjugation efficiency exceeding 90% in a pilot-scale model reaction.

Process development for biotin-streptavidin bridging in ultrasensitive single-molecule array (Simoa) technology demands that the NHS ester coupling onto a rabbit monoclonal detection antibody be halted when the biotin-to-antibody ratio reaches precisely 2.0–2.5, because values above 3.0 induce steric interference with the capture antibody-paratope complex inside the 2.5 µm diameter microwells of the Quanterix SR-X instrument. The manufacturing process uses a stopped-flow reactor configuration where antibody at 1.0 mg/mL in 50 mM sodium carbonate, pH 9.0, is mixed with a 50 µM solution of the NHS ester in DMSO at a volume ratio of 100:1, achieving a final molar input ratio of 6:1. The mixture advances through a coiled polyetheretherketone tubing of 1.0 mm inner diameter maintained at 20 °C, with a residence time of exactly 8.5 min before quenching with 0.1 M glycine in a downstream T-connector. Following quenching, the conjugate is purified on a Protein A HP spin column and formulated into a buffer consisting of 50 mM Tris, 150 mM NaCl, 0.05% ProClin 300, pH 7.4. Finished biotinylated antibody released for kit assembly must present less than 0.5% free biotin as measured by competition ELISA, a specification aligned with ISO 13485:2016 Clause 8.2.6 for monitoring and measurement of product. The terminal product is a Simoa bead reagent kit component used in neurology investigational biomarker panels, where sub-part-per-trillion sensitivity renders any cross-batch variation in biotinylation level a root cause for non-conforming standard curve slopes.